Total VTE
| . | RECORD 1 (hip) . | RECORD 2 (hip) . | RECORD 3 (knee) . | RECORD 4 (knee) . |
|---|---|---|---|---|
| Rivaroxaban | ||||
| n | 1595 | 864 | 824 | 965 |
| Endpoint | 18 (1.1%) | 17 (2.0%) | 79 (9.6%) | 67 (6.9%) |
| Enoxaparin | ||||
| n | 1558 | 869 | 878 | 959 |
| Endpoint | 58 (3.7%) | 81 (9.3%) | 166 (18.9%) | 97 (10.1%) |
| . | RECORD 1 (hip) . | RECORD 2 (hip) . | RECORD 3 (knee) . | RECORD 4 (knee) . |
|---|---|---|---|---|
| Rivaroxaban | ||||
| n | 1595 | 864 | 824 | 965 |
| Endpoint | 18 (1.1%) | 17 (2.0%) | 79 (9.6%) | 67 (6.9%) |
| Enoxaparin | ||||
| n | 1558 | 869 | 878 | 959 |
| Endpoint | 58 (3.7%) | 81 (9.3%) | 166 (18.9%) | 97 (10.1%) |
Total VTE = occurrence of: any DVT (symptomatic or asymptomatic), nonfatal PE, or death of any cause in RECORD studies of rivaroxaban after major orthopedic surgery.12-15 All differences favor rivaroxaban, and all reach statistical significance (P < .05).